Biotechnology Businesses for Sale and Investment

E-commerce portal for rapid medical diagnostic tests that is currently in pre-revenue stage. - The ideal buyer for this website is likely an individual or business looking to establish an online presence in the medical supplies market without the need for high initial capital investment in stock or infrastructure. - This could include entrepreneurs, small businesses, or individuals looking to diversify their portfolios. - The buyer should be interested in leveraging the potential of e-commerce and willing to invest time and effort into promoting the website to generate sales. - No licenses are necessary for retail of rapid tests in the UK market. The buyer will get the supplier details and can acquire stock from a reputed German distributor.

Our brand is the world’s first instant methanol detection test, designed to protect consumers from deadly counterfeit alcohol. Our rapid-detection strip provides a fast, portable, and affordable solution for travelers, bars, hotels, and government agencies. HQ: Planned Dubai launch for cost-effective operations, global scalability, and safety of transactions. Market opportunity: $60B+ counterfeit alcohol crisis worldwide (1,000s of people die from methanol poisoning each year! and there is no way to test the drinks) Revenue model: • Direct-to-consumer (DTC): Sold online (Amazon, TikTok Shop, website) through major online retailers worldwide. • Bulk B2B sales: Hotels, universities, hospitals, pharmacies, retailers, train stations, bars, duty-free retailers. Globally. • Licensing deals: Partnering with biotech firms & alcohol brands for distribution. Projected price: ~$19.99 per pack, we must aim to have a 70% margin. Projected sales growth: •Year 1: 50K units → $1M revenue. •Year 2: 250K units → $5M revenue. •Year 3: 1M+ units → $20M+ revenue. Exit strategy: Sell to a biotech or alcohol safety giant etc for $50M+ or license the technology for passive royalties. Promoter experience & business relationships: • Founder: Experienced entrepreneur with expertise in luxury branding, viral marketing, and scaling consumer products with the globally recognized superstars behind the previous brand I have developed. • Scientific & business team: Partnering with chemists & biotech advisors to ensure product reliability. • Distribution talks: Engaging bars, airlines, hotels, etc. • Investor network: Seeking 1-2 strategic investors to fund final development and global launch. This product is positioned to disrupt a billion-dollar problem and scale as the go-to alcohol safety brand worldwide. Some of the brightest minds in biotech and science will be on board. The product is not medicine and does not need to be FDA-approved as we will market it as a consumer product (like pregnancy tests). The product will deliver a 90% accuracy which is enough to save millions of lives. This is a once-in-a-lifetime opportunity and we are applying for patents already.

Situated in Fremont, this business specializes in manufacturing assay kits for biochemicals, enzymes, and ions, serving primarily the life science and biotechnology sectors. - The company focuses on providing research products that are designed to be user-friendly, highly reproducible, and cost-effective, potentially advancing research in serious health conditions such as cancer, diabetes, and neurodegenerative diseases. - With a global network of 30-35 distributors, the company exports 90% of its products mainly to European and Asian markets, including key countries like China, Korea, and Japan. - The production capacity stands at manufacturing 500 kits per day, ensuring steady supply capabilities to meet the needs of international research communities. - Orders are fulfilled on a weekly basis, facilitating consistent supply and robust support for ongoing research projects worldwide. - The business is not yet profitable, as its revenue is being reinvested into expansion and growth efforts. - By focusing on quality and affordability, the company distinguishes itself as a competitive player in the assay kit market, supporting vital research across continents.

The company is strategically positioned in the biotechnology sector, with plans to specialize in high-demand services such as flow cytometry and cell culture, tailored to support pharmaceutical, biotech, and diagnostic companies. - Despite being registered 4 years ago, the company has yet to start operations but has laid the groundwork through strategic collaborations and grant submissions totalling approximately USD 40 million, showcasing a strong potential for funding acquisition. - The promoter's extensive background, with a PhD in cell biology and two decades of research experience, provides a strong foundation for the company's technical expertise and leadership. - Possession of distribution rights for crucial research kits and therapeutic proteins indicates early-stage readiness to supply essential products to the research community. - The company maintains strategic collaborations with antibody-based firms, enhancing its capability to provide comprehensive solutions for advanced therapeutic and research needs. - Haverhill, the company's location, provides access to a strategic geographical position that can facilitate partnerships with key biotech and pharmaceutical players. - The planned service offerings, including advanced flow cytometry and specialized cell culture services, underscore the company's commitment to supporting cutting-edge research with reliable and customizable solutions.

Established player in the biomedical devices sector, operating from Chennai with a focus on servicing bio-medical equipment and consultancy services. - Currently employs a dedicated team of 8 skilled professionals committed to excellence in service delivery. - Recognized as one of the top 25 companies with innovative products by the Wadhwani Foundation CEO, highlighting its commitment to quality and innovation. - Signed MOU with VIT University, Vellore, and IITM for internship training programs for students, fostering educational collaboration and real-world experience. - Successfully served over 550 hospitals, showcasing a strong market presence and customer trust. - Maintains strategic partnerships with Original Equipment Manufacturers (OEMs) to ensure seamless device procurement. - The promoter brings 33 years of industry experience, having held key positions in leading hospitals and multinational corporations, enhancing business credibility. - Registered with the Ministry of Corporate Affairs (MCA), ensuring compliance with legal frameworks within the industry.

Planning to establish a cannabis plantation to produce anesthetic drugs. - Seeking foreign investors to comply with the local law, which mandates that only foreigners can hold a license for cannabis plantations. - The promoter is an Ayurvedic doctor with 30 years of experience in the industry. - We will be applying for licenses, and only foreigners are eligible to hold them. - Our plan is to establish a cannabis plantation and export cannabis anesthetic drugs through distributors worldwide. - The drugs will be specifically formulated for anesthesia purposes.

1. Greece's advantageous climate and geographic location make it an ideal setting for the development of a cannabis industry, leveraging abundant sunlight and easy access to European markets. 2. The company has received a substantial grant of EUR 840,000 from the development law, providing a financial boost with no repayment expectations. 3. Possessing a medical cannabis license enabling the production of up to 45 different products, the business has the potential to be among the top 10 distributors in Greece, positioning itself for significant market share. 4. The company holds licenses for cultivating and processing medicinal cannabis plants, focusing on the cultivation and processing of medicinal cannabis on a plot area of approximately 9,000 m2 in Nea Anchialos. 5. With the intention to achieve one of the highest levels of medical cannabis production in Europe over the next five years, the business has the potential to generate a gross profit of over 5 million euros. 6. The company has obtained the necessary legal documentation and licenses, including the first Installation approval license, to expedite the construction of a successful pharmaceutical cannabis facility, positioning it ahead of many others in the industry. 7. As a pioneer in Greece's medical cannabis sector, the business has the opportunity to capitalize on the location and the needs.

An AI-enhanced physics-based drug discovery company. - Integrates artificial intelligence, computational chemistry, and peptide science to expedite therapeutic compound discovery and optimize leads. - Discovers and optimizes active, specific, non-toxic, and patentable small molecules delivering superior drug candidates. - The company boasts a diverse clientele, with more than 6 clients including reputable organizations such as Deloitte Belgium, B. Braun, Fresenius Kabi, and UCB Pharma. - The company currently generates revenue through the provision of management consulting services for pharmaceutical and biotech companies. It operates on a per-service-based charging model. - Company is currently engaged in the development of brain-specific and selective butyrylcholinesterase inhibitors for the treatment of severe Alzheimer's. - The business is not yet profitable as it is reinvesting its revenue into research and development activities, - The company has 2 additional contract employees for R&D activities.

High potential company with a science-proven, patented beverage for acute alcohol intoxication. - Our product is a science-based beverage designed for the resolution of acute alcohol toxicity. - The company has developed this product over the past 3 years and is now seeking early-stage investors to bring it to market. - We are in discussions with approximately 18 major clients in the pharmaceutical industry, including pharma product buyers and large pharmacies such as Audifarma and Eticos Serrano, to ensure effective product introduction and distribution. - Our team has over 4 years of successful experience in launching pharmaceutical products in the Colombian market. - We will be available in the market in the next few months. - Our target audience is the alcohol consumption market, focusing on providing a solution for alcohol elimination in intoxicated individuals. - The company is currently in the pre-seed stage. - We are planning to establish a manufacturing unit soon, with a production capacity of 100,000 units per month. - Company has incorporation license and INVIMA registration (license from the National Food and Drug Surveillance Institute)

The company is a pharmaceutical and healthcare business based in Cambridge, specializing in drug discovery and development of novel drug compounds. - The company has a small team of 5 employees, with promoters who have over two decades of experience in pharmacology, having worked as scientists at renowned universities in the United Kingdom. - The company's research and development infrastructure is well-established, and it also offers managed print services and contract research in addition to drug development. - The focus of the company's research is on finding a cure for Parkinson's disease, with over 130 tests conducted on the drug compound showing a 75% success rate, with an expected increase to over 90% within the next 2 years. - Upon launch to the public, the company anticipates generating over 90% in profits. - The company's drug discovery and development process is supported by Indian scholar scientists based in the UK, adding a diverse and skilled team to its research efforts. - All research documents related to the drug compounds and trials are available for review, providing transparency and insight into the company's research and development activities.

The company is a bio-medical startup based in Mumbai with a current manufacturing capacity of 20,000 units and is seeking investment to scale marketing, distribution, and assembly. - The heart rate monitor is the top-selling product, with an average of 200 units sold per month through online channels such as the company's website and Amazon. Revenue sources are diversified, with 40% of sales revenue coming from Amazon and 60% from the company's website. The company utilizes Ship Rocket and Amazon for logistics. - The company's current sales are entirely business-to-consumer (B2C) - The company has garnered interest from Bridge Health and Fitterfly for the use of its product in BP reduction programs, showcasing the potential for further B2B partnerships. - The heart rate monitor is currently sold at an introductory price of INR 1,999 for the first 1,000 devices, with the regular price set at INR 3,499. The company aims to sell approximately 1 lakh units by the end of the year. - The product current has a +/- 2 points tolerance, which shows they are 98% accurate. - Collaborating with telemedicine doctors. - The company has currently outsourced manufacturing with a manufacturing capacity of approximately 20,000 units manufactured a month and we have our own testing and assembly rigs to avoid any leaking of design and work. - The business already has a ready stock of more than 10,000 units in inventory and is sending them for testing to its partners. - The business holds the necessary GST certificate & an ISO 13485 certificate.